Enveric Biosciences (ENVB) announced the successful completion of seven-day dose range finding toxicology studies in two preclinical species for its lead drug candidate, EB-003. The results define the maximum tolerated dose and represent a key pipeline advancement landmark supporting the company’s IND-enabling activities and preparation for first-in-human clinical trials.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: atai Life Sciences, Cybin report earnings results
- Psychedelic: Clearmind completes site initiation for CMND-100 trial
- Enveric Biosciences receives second notice of allowance from USPTO for EVM401
- Psychedelic: Clearmind expands trial for Alcohol Use Disorder
- Enveric Biosciences announces results of EB-003 preclinical model